Stem Cell Research (Aug 2021)

CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation

  • Janik Boehnke,
  • Salim Atakhanov,
  • Marcelo A.S. Toledo,
  • Herdit M. Schüler,
  • Stephanie Sontag,
  • Nicolas Chatain,
  • Steffen Koschmieder,
  • Tim H. Brümmendorf,
  • Rafael Kramann,
  • Martin Zenke

Journal volume & issue
Vol. 55
p. 102490

Abstract

Read online

The chemokine CXCL4/platelet factor 4 (PF4) gene, a key player in myelofibrosis, was knocked out by CRISPR/Cas9 in induced pluripotent stem cells (iPS cells) of a polycythemia vera (PV) patient with JAK2 V617F mutation. Two CXCL4KO iPS cell lines with and without JAK2 V617F mutation (UKAi002-B-1 and UKAi002-A-1, respectively) were generated. CXCL4KO iPS cells showed deletion of exon 1 and complete loss of CXCL4 protein. Pluripotency of iPS cells was confirmed by expression of pluripotency markers and trilineage differentiation. CXCL4KO iPS cells are expected to provide a valuable tool for investigating the role of CXCL4 in human diseases.

Keywords